{
  "source": "PA-Notification-Taltz.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1183-10\nProgram Prior Authorization/Notification\nMedication Taltz® (ixekizumab)*\n*Taltz is excluded from coverage for the majority of our benefits\nP&T Approval Date 5/2016, 3/2017, 2/2018, 2/2019, 9/2019, 7/2020, 7/2021, 7/2022,\n7/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nTaltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of\npatients aged 6 years or older with moderate to severe plaque psoriasis who are candidates for\nsystemic therapy or phototherapy. It is also indicated for the treatment of adult patients with\nactive psoriatic arthritis, active ankylosing spondylitis or non-radiographic axial\nspondyloarthritis with objective signs of inflammation.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Taltz* will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nSiliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Taltz will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Taltz therapy\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(2) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nSiliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumian",
    "Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nSiliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis\n1. Initial Authorization\na. Taltz* will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Taltz will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Taltz therapy\n-AND-\n(2) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis\n1. Initial Authorization\n© 2024 UnitedHealthcare Services, Inc.\n2\na. Taltz* will be approved based on both of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis or active non-radiographic axial\nspondyloarthritis\n-AND-\n(2) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumia",
    "eiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Taltz* will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Taltz therapy\n-AND-\n(2) Patient is not receiving Taltz in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Taltz is typically excluded from coverage. Tried/failed criteria may be in place. Please refer to plan\nspecifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity, Supply limits and/or Step Therapy may be in place.\n4. Reference:\n1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Co.; August 2024.\n© 2024 UnitedHealthcare Services, Inc.\n3\nProgram Prior Authorization/Notification - Taltz (ixekizumab)\nChange Control\n5/2016 New program\n3/2017 Annual review with no change to criteria. Updated reference.\n2/2018 Updated background and added criteria for new indication of psoriatic\narthritis. Updated reference.\n2/2019 Annual review with no change to criteria. Updated reference.\n9/2019 Updated background and criteria",
    "d background and added criteria for new indication of psoriatic\narthritis. Updated reference.\n2/2019 Annual review with no change to criteria. Updated reference.\n9/2019 Updated background and criteria to include new indication for active\nankylosing spondylitis. Added coverage exclusion statement. Updated\nreference.\n7/2020 Updated background and criteria to include new indication for active\nnon-radiographic axial spondyloarthritis. Changed reauthorization\nduration to 12 months. Updated reference.\n7/2021 Annual review with no changes to criteria.\n7/2022 Annual review with no changes to criteria. Updated examples to align\nwith Taltz Medical Necessity, added state mandate disclaimer, moved\nlocation of exclusion statement and updated reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n11/2024 Annual review with no changes to coverage criteria. Updated\nreference.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}